The global acute myeloid leukaemia market reached $1bn in 2017 and is estimated to reach $2.8bn by 2022

NEW YORK, March 26, 2019 /PRNewswire/ -- Chemotherapy, Targeted Therapy, Cytarabine, Daunorubicin, Midostaurin, Enasidenib

Read the full report: https://www.reportlinker.com/p05605443/?utm_source=PRN

The global acute myeloid leukaemia market reached $1bn in 2017 and is estimated to reach $2.8bn by 2022. In 2017, the chemotherapy segment held 69% of the global acute myeloid leukaemia market.

How this report will benefit you
Read on to discover how you can exploit the future business opportunities emerging in this sector.
In this brand new 135-page report you will receive 92 charts– all unavailable elsewhere.
The 135-page report provides clear detailed insight into the acute myeloid leukaemia market. Discover the key drivers and challenges affecting the market.
By ordering and reading our brand-new report today you stay better informed and ready to act.

Report Scope
- Global Acute Myeloid Leukaemia Market from 2018-2028

Forecast of the Global Acute Myeloid Leukaemia market by Treatment Type and Product Type:
- Chemotherapy: Cytarabine, Daunorubicin, Others
- Targeted Therapy: Midostaurin, Enasidenib, Others

This report provides individual revenue forecasts to 2028 for these regional and national markets:
- North America: US, Canada, and Mexico
- Europe: Germany, France, United Kingdom, Italy, Spain, Russia, and rest of Europe
- Asia-Pacific: Japan, China, Australia, South Korea, India, and rest of Asia-Pacific
- LAMEA: Brazil, Saudi Arabia, Republic of South Africa, Turkey, and rest of LAMEA

Our study discusses the selected leading companies that are the major players in the acute myeloid leukaemia market:
- Bristol-Myers Squibb Company
- Celgene
- Clavis Pharma ASA
- Daiichi Sankyo
- Eisai
- GSK
- Novartis
- Roche
- Sunesis Pharmaceuticals
- Teva
- This report discusses factors that drive and restrain the acute myeloid leukaemia market. This report also discusses the opportunities that can be tapped in this market.
- This report also discusses several new agents that are in development for the treatment of acute myeloid leukaemia.

Read the full report: https://www.reportlinker.com/p05605443/?utm_source=PRN

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________
Contact Clare: clare@reportlinker.com
US: (339)-368-6001
Intl: +1 339-368-6001

View original content:http://www.prnewswire.com/news-releases/the-global-acute-myeloid-leukaemia-market-reached-1bn-in-2017-and-is-estimated-to-reach-2-8bn-by-2022--300818794.html

SOURCE Reportlinker